These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23553099)

  • 1. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
    Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
    Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
    Kang Y; Hong JA; Chen GA; Nguyen DM; Schrump DS
    Oncogene; 2007 Jun; 26(30):4394-403. PubMed ID: 17260018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structural complexity of the human BORIS gene in gametogenesis and cancer.
    Pugacheva EM; Suzuki T; Pack SD; Kosaka-Suzuki N; Yoon J; Vostrov AA; Barsov E; Strunnikov AV; Morse HC; Loukinov D; Lobanenkov V
    PLoS One; 2010 Nov; 5(11):e13872. PubMed ID: 21079786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity.
    Filippova GN; Qi CF; Ulmer JE; Moore JM; Ward MD; Hu YJ; Loukinov DI; Pugacheva EM; Klenova EM; Grundy PE; Feinberg AP; Cleton-Jansen AM; Moerland EW; Cornelisse CJ; Suzuki H; Komiya A; Lindblom A; Dorion-Bonnet F; Neiman PE; Morse HC; Collins SJ; Lobanenkov VV
    Cancer Res; 2002 Jan; 62(1):48-52. PubMed ID: 11782357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.
    Renaud S; Pugacheva EM; Delgado MD; Braunschweig R; Abdullaev Z; Loukinov D; Benhattar J; Lobanenkov V
    Nucleic Acids Res; 2007; 35(21):7372-88. PubMed ID: 17962299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTCF and BORIS in genome regulation and cancer.
    Marshall AD; Bailey CG; Rasko JE
    Curr Opin Genet Dev; 2014 Feb; 24():8-15. PubMed ID: 24657531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers.
    Filippova GN; Lindblom A; Meincke LJ; Klenova EM; Neiman PE; Collins SJ; Doggett NA; Lobanenkov VV
    Genes Chromosomes Cancer; 1998 May; 22(1):26-36. PubMed ID: 9591631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma.
    Loukinov DI; Pugacheva E; Vatolin S; Pack SD; Moon H; Chernukhin I; Mannan P; Larsson E; Kanduri C; Vostrov AA; Cui H; Niemitz EL; Rasko JE; Docquier FM; Kistler M; Breen JJ; Zhuang Z; Quitschke WW; Renkawitz R; Klenova EM; Feinberg AP; Ohlsson R; Morse HC; Lobanenkov VV
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6806-11. PubMed ID: 12011441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Widespread expression of BORIS/CTCFL in normal and cancer cells.
    Jones TA; Ogunkolade BW; Szary J; Aarum J; Mumin MA; Patel S; Pieri CA; Sheer D
    PLoS One; 2011; 6(7):e22399. PubMed ID: 21811597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
    Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
    Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.
    Pugacheva EM; Rivero-Hinojosa S; Espinoza CA; Méndez-Catalá CF; Kang S; Suzuki T; Kosaka-Suzuki N; Robinson S; Nagarajan V; Ye Z; Boukaba A; Rasko JE; Strunnikov AV; Loukinov D; Ren B; Lobanenkov VV
    Genome Biol; 2015 Aug; 16(1):161. PubMed ID: 26268681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cell cycle role for the epigenetic factor CTCF-L/BORIS.
    Rosa-Garrido M; Ceballos L; Alonso-Lecue P; Abraira C; Delgado MD; Gandarillas A
    PLoS One; 2012; 7(6):e39371. PubMed ID: 22724006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivation.
    Pugacheva EM; Tiwari VK; Abdullaev Z; Vostrov AA; Flanagan PT; Quitschke WW; Loukinov DI; Ohlsson R; Lobanenkov VV
    Hum Mol Genet; 2005 Apr; 14(7):953-65. PubMed ID: 15731119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene BORIS.
    Suzuki T; Kosaka-Suzuki N; Pack S; Shin DM; Yoon J; Abdullaev Z; Pugacheva E; Morse HC; Loukinov D; Lobanenkov V
    Mol Cell Biol; 2010 May; 30(10):2473-84. PubMed ID: 20231363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
    Loukinov D; Ghochikyan A; Mkrtichyan M; Ichim TE; Lobanenkov VV; Cribbs DH; Agadjanyan MG
    J Cell Biochem; 2006 Aug; 98(5):1037-43. PubMed ID: 16741971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer.
    Fiorentino FP; Macaluso M; Miranda F; Montanari M; Russo A; Bagella L; Giordano A
    Mol Cancer Res; 2011 Feb; 9(2):225-33. PubMed ID: 21325284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression analysis of BORIS during pluripotent, differentiated, cancerous, and non-cancerous cell states.
    Soltanian S; Dehghani H; Matin MM; Bahrami AR
    Acta Biochim Biophys Sin (Shanghai); 2014 Aug; 46(8):647-58. PubMed ID: 24928684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.